Severity of pain on day 3 · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes severity of pain on day 3 compared with standard treatment alone (very low certainty).
1 finding from 1 review
Duration of clinical symptoms: fever and rash (days) · children diagnosed with Kawasaki disease
1 finding from 1 review
Time for laboratory parameters to normalise: CRP, ESR (days) Duration: N/A · children diagnosed with Kawasaki disease
1 finding from 1 review
Length of hospital stay · children diagnosed with Kawasaki disease
1 finding from 1 review
Days missed from work or school · patients with sore throat
1 finding from 1 review
28‐Day all‐cause mortalitya · children and adults with sepsis
Corticosteroids probably leads to lower 28‐Day all‐cause mortalitya compared with placebo or usual care (moderate certainty).
1 finding from 1 review
ICU length of stay (general intensive care patients) · children and adults with sepsis
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · children and adults with sepsis
1 finding from 1 review
Early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28; day 60; and in hospital · adults with acute respiratory distress syndrome
Corticosteroids showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28;… compared with control (low certainty).
1 finding from 1 review
Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome
It is very uncertain whether corticosteroids changes late all‐cause mortality ( > 3 months) Reported at: 180 days compared with control (very low certainty).
1 finding from 1 review
Duration of mechanical ventilation · adults with acute respiratory distress syndrome
1 finding from 1 review
Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome
1 finding from 1 review
Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes ‐ prednisone (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
Corticosteroids showed no clear difference in behavioural changes ‐ prednisone (0.75 mg/kg/day) compared with placebo (moderate certainty).
1 finding from 1 review
Severe nausea 17th day · Pregnant women with hyperemesis gravidarum
It is very uncertain whether corticosteroids changes severe nausea 17th day compared with promethazine (very low certainty).
1 finding from 1 review
Vomiting · Pregnant women with hyperemesis gravidarum
It is very uncertain whether corticosteroids changes episodes of vomiting 17th day compared with promethazine (very low certainty).
1 finding from 1 review
Intervention side effects: drowsiness 48hrs and 3‐10 days · Pregnant women with hyperemesis gravidarum
Corticosteroids showed no clear difference in intervention side effects: drowsiness 48hrs and 3‐10 days compared with promethazine (low certainty).
1 finding from 1 review